ORLEANS, ON, June 21, 2019 /CNW Telbec/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that all matters presented for approval at the Corporation’s annual general and special meeting (the “Meeting“) of shareholders of the Corporation held in Montréal, province of Québec, on June 20, 2019, were approved.
Election of Directors and Resolutions
All of the nominees listed in Tetra’s management information circular dated May 22, 2019 (the “Circular“) were elected as directors of the Corporation until the next annual meeting of shareholders or until their successors are elected or appointed, to the exception of Mr. Benoit Chotard, whose nomination for election as director of the Corporation was withdrawn by the Corporation after he announced his resignation, effective as of June 14, 2019, as indicated in the press release issued on June 14, 2019. The results of the vote were as follows:
|Nominee||Votes For||% For||Votes Withheld||% Withheld|
|Dr. Guy Chamberland||19,787,470||99.68||64,453||0.32|
|Dr. W.M. (Bill) Cheliak||19,793,048||99.70||58,875||0.30|
The proposal to appoint McGovern, Hurley, Cunningham, LLP as auditor of the Corporation and to authorize the board of directors to fix the remuneration to be paid to the auditor, as presented in the Circular, was approved (99.78%) by the shareholders at the Meeting.
The amended and restated stock option plan of the Corporation as described in the Circular was approved (89.92%) by the shareholders at the Meeting. The amendment provides that the aggregate number of common shares reserved for the issuance under stock options granted to insiders, as a group, at any point in time, together with all the Corporation’s previously established and outstanding stock option plans or grants, will not exceed 10% of the issued common shares.
The proposed amendment to the articles of incorporation of the corporation, as fully detailed in the Circular, was also approved (99.07%) by the shareholders at the Meeting.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical multifaced corporation with its primary focus in cannabinoid-based drug discovery and development with a clinical trial program aimed at bringing novel drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma’s subsidiary, Tetra Natural Health, also focuses on the development and commercialization of natural health and self-care products as well as the sale of its hemp energy drinks.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of CAUMZ and its other drug candidates, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Tetra Bio-Pharma Inc
For further information: Tetra Bio-Pharma Inc.: Sabino Di Paolo, Chief Financial Officer, 613-721-2919,